MUC5AC expression decrease correlates with the decline in rates of severe asthma exacerbations post bronchial thermoplasty

J. Chakir (Québec, QC, Canada)

Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Session: Novel mechanisms and treatments for asthma
Session type: Oral Presentation
Number: 279
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Chakir (Québec, QC, Canada). MUC5AC expression decrease correlates with the decline in rates of severe asthma exacerbations post bronchial thermoplasty. 279

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The bronchial expression of vanin in moderate to severe asthma
Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets
Year: 2019

Changes in lung function and airway eosinophilia after reduction of ICS treatment and recurrence of asthmatic symptoms
Source: Eur Respir J 2003; 22: Suppl. 45, 547s
Year: 2003

An imbalanced airway microbiota correlates with greater peak flow decline in virus-induced asthma exacerbations
Source: International Congress 2017 – COPD: microbiome composition and the role of antibiotics
Year: 2017




The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients
Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Year: 2020


Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017


Maximal airway response in patients with asthma and cough variant asthma
Source: Annual Congress 2007 - COPD, sarcoidosis, idiopathic pulmonary fibrosis, cystic fibrosis, gastro-oesophageal reflux and cough variant asthma - pathogenesis and differential diagnosis
Year: 2007


Metabolic differences in bronchial epithelium from asthma patients and impact of bronchial thermoplasty
Source: Virtual Congress 2020 – Metabolic alterations and ageing in lung disease
Year: 2020




Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


R411 treatment reduces asthma exacerbations and attenuates FEV1 fall following steroid withdrawal in moderate asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 252s
Year: 2005

Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005

Severe exacerbations predict excess lung function decline in asthma
Source: Eur Respir J 2007; 30: 452-456
Year: 2007



The influence of smoking on the formation of cold airway hyperresponsiveness and destructive-cytolytic profile of goblet cells in asthma patients
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018


Relationship between bronchial hyperresponsiveness and response to β2-agonists in steroid-naïve patients with mild asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 503s
Year: 2002

Is there any day variability of respiratory function and airway inflammation in children with mild asthma?
Source: Eur Respir J 2006; 28: Suppl. 50, 264s
Year: 2006

Heterogeneous response of airway eosinophilia to biologics in severe asthma patients
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009

Omalizumab significantly improves FEV1 in patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005

A treatment regime based on induced sputum eosinophilia does not result in a reduction in exacerbations in refractory severe asthmatics
Source: Annual Congress 2008 - Severe asthma: a heterogeneous clinical entity
Year: 2008



Mepolizumab improves small airway function in severe eosinophilic asthma
Source: International Congress 2018 – The value of lung function testing in various pathophysiological conditions
Year: 2018

Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008